Systemic sclerosis in 3 US ethnic groups: A comparison of clinical, sociodemographic, serologic, and immunogenetic determinants

Seminars in Arthritis and Rheumatism

Volumn 30, Issue 5, 2001, Pages 332-346

  Reveille, John D ^a,b,c,d,e   Fischbach, Michael ^a,b,c,d,f   McNearney, Terry ^a,b,c,d,g   Friedman, Alan W ^a,b,c,d,e   Aguilar, Martha B ^a,b,c,d,e   Lisse, Jeffrey ^a,b,c,d,g   Fritzler, Marvin J ^a,b,c,d   Ahn, Chul ^a,b,c,d,h   Arnett, Frank C ^a,b,c,d,e  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e UTHHSC   (United States)

^f UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^h HTH HSC   (United States)

Author keywords

Autoantibodies; Ethnicity; Immunogenetics; Scleroderma; Sociodemographic factors; Systemic sclerosis

Indexed keywords

CENTROMERE ANTIBODY; FIBRILLARIN; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR ANTIGEN; RIBONUCLEOPROTEIN; RIBONUCLEOPROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; ETHNIC GROUP; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; SOCIOECONOMICS; SYSTEMIC SCLEROSIS; UNITED STATES;

EID: 0035044928     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1053/sarh.2001.20268     Document Type: Article

References (50)

1. The epidemiology of systemic sclerosis (scleroderma) among male US veterans
2. Epidemiology of fatal systemic sclerosis (diffuse scleroderma)
3. Predictors of survival in systemic sclerosis (scleroderma)
4. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma
5. Demographic differences in the frequencies of scleroderma-related autoantibodies
6. Racial differences in the frequencies of scleroderma-related autoantibodies
7. HLA and autoimmunity in scleroderma (systemic sclerosis)
8. Survival in systemic lupus erythematosus. A multivariate analysis of demographic factors
9. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death
10. Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status
11. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus
12. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
13. Skin thickness and collagen content in progressive systemic sclerosis (scleroderma) and localized scleroderma
14. Is it possible to reduce observer variability in skin score assessment of scleroderma?
15. Outcome measurement in scleroderma clinical trials
16. Health care seeking behavior in fibromyalgia: Associations with pain thresholds, symptom severity, and psychiatric morbidity
17. The measurement of fatigue: A new instrument
18. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): An immunogenetic, serologic, and clinical analysis
19. Contrasting molecular patterns of MHC class II alleles associated with the anti-Sm and anti-RNP precipitin autoantibodies in systemic lupus erythematosus
20. Association of amino acid sequences in the HLA-DQB1 first domain with the anti-topoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis)
21. Learned helplessness in systemic lupus erythematosus: Analysis using the rheumatology attitudes index
22. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
23. The MOS short-form general health survey: Reliability and validity in a patient population
24. Concurrent validity of the health assessment questionnaire disability index in scleroderma
25. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort
26. Racial differences in scleroderma among women in Michigan
27. Frequencies of scleroderma-related autoantibodies in patients meeting American College of Rheumatology criteria for systemic sclerosis: Reply
28. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis
29. Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus
30. HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a native American population with a high prevalence of scleroderma (systemic sclerosis)
31. Increased frequency of DR5 in scleroderma
32. DNA-DR typing shows HLA-DRw11 RFLPs are increased in frequency in both progressive systemic sclerosis and CREST variants of scleroderma
33. HLA-DR antigens in progressive systemic sclerosis (scleroderma)
34. Association of HLA-DR5 (DR11) with systemic sclerosis (scleroderma) in Mexican patients
35. A molecular and serologic analysis of the major histocompatibility complex and complement component C4 in systemic sclerosis
36. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody
37. Severe systemic sclerosis with anti-topoisomerase I antibodies is associated with an HLA-DRw11 allele
38. Immunogenetic associations of scleroderma-related antinuclear antibodies
39. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma)
40. Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: A serological and HLA study
41. The centromere kinesin-like protein, CENP-E: An autoantigen in systemic sclerosis
42. Early undifferentiated connective tissue disease III: Outcome and prognostic indicators in early scleroderma (systemic sclerosis)
43. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease